Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases

European Journal of Nuclear Medicine

Volumn 23, Issue 8, 1996, Pages 932-939

  Mansi, Luigi ^a   Rambaldi, Pier Francesco ^a   Procaccini, Eugenic ^a   Di Gregorio, Fernando ^a   Laprovitera, Adelina ^a   Pecori, Biagio ^a   Del Vecchio, Walter ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Breast cancer; Node metastases; Scintimammography; Technetium 99m tetrofosmin

Indexed keywords

TETROFOSMIN TC 99M;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BODY POSITION; BREAST CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; QUANTITATIVE DIAGNOSIS; SCINTISCANNING; TUMOR VOLUME;

EID: 0029737023     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01084367     Document Type: Article

References (56)

1. Harris JR, Hellmann S. Natural history of breast cancer. In. Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases, 2nd edn. Philadelphia: Lippincott; 1991: 165-181.
2. Rosen PP. The pathology of invasive breast carcinoma. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases, 2nd edn. Philadelphia: Lippincott; 1991: 245-296.
3. Harris JR, Henderson IC. Staging and prognostic factor. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases, 2nd edn. Philadelphia: Lippincott; 1991: 327-346.
4. Burns PE, Grace MG, Lees AW, etal. False negative mammograms delay diagnosis of breast cancer. N Engl J Med 1978; 299: 201-202.
5. Kopans DB. The positive predictive value of mammography. AJR 1992; 158: 521-526.
6. Sickles EA, Mammographic feature of 300 consecutive nonpalpable breast cancers. AJR 1986; 146: 661-663.
7. Mann BD, Giuliano AE, Bassett LW, etal. Delayed diagnosis of breast cancer as a result of normal mammograms. Arch Surg 1983; 118: 23-25.
8. Feig SA, Shuber GA, Patchelskly A. Analysis of clinically occult and mammographically occult breast tumors. AJR 1977; 128: 403-408.
9. Kalisher L. Factors influencing false negative rates in xeromammography. Radiology 1979; 133: 297-301.
10. Fajardo LL, Harvey JA, McAleese KA, Roberts CC, Granstrom P. Breast cancer diagnosis in women with subglandular silicone-gel filed augmentation implants. Radiology 1995; 194: 859-862.
11. Jackson VP, Hendrick RE, Kerg SA, etal. Imaging of the radiographically dense breast. Radiology 1993; 198: 297-301.
12. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancer missed at screening mammography. Radiology 1992; 184: 613-617.
13. Recht A, Sadowsky NL, Cady B. Clinical problems in follow-up of patients following conservative surgery and radiotherapy. Surg Clin North Am 1990; 70: 1179-1186.
14. Jackson VP. The role of US in breast imaging. Radiology 1990; 177: 305-311.
15. Bassett LW, Kimme-Smith C. Breast ultrasound. AJR 1991; 156: 449-455.
16. Zonderland HM, Hermans J, Holscher HC, Schipper J, Obermann WR. Additional value of US to mammography: profit and loss. Eur Radiol 1994; 4: 511-516.
17. Kinne DW, Kopans DB. Physical examination and mammography in the diagnosis of breast disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW. Breast diseases, 2nd ed. Philadelphia: Lippincott, 1991: pp 81-106.
18. Harms SE, Flaming DP, Hesley KL, etal. MR imaging of the breast with rotating delivery of excitation of resonance: clinical experience with pathological correlation. Radiology 1993; 187: 493-501.
19. Franceschi D, Crowe J, Zollinger R, etal. Breast biopsy for calcifications in nonpalpable breast lesions. Arch Surg 1990; 125: 170-173.
20. Franceschi D, Crowe J, Lie S, etal. Not all nonpalpable breast cancers are alike. Arch Surg 1991; 126: 967-971.
21. Patel JJ, Gartel PC, Smallwood JA, etal. Fine needle aspiration cytology of breast masses: an evaluation of its accuracy and reasons for diagnostic failure. Ann R Coll Surg Engl 1987; 69: 156-159.
22. Piccolo S, Lastoria S, Mainolfi C, Muto P, Bazzicalupo L, Salvatore M. Technetium-99m-methylene diphosphonate seinti-mammography to image primary breast cancer. J Nucl Med 1995; 36: 718-724.
23. Waxman AD, Ramanna L, Memsic LD, Foster CE, Silberman AW, Gleischmann SH, Brenner RJ, Brachmann MB, Knhar CJ, Yadegar J. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993; 34: 18-23.
24. Cimitan M, Volpe R, Candiani E, Gusso G, Ruffo R, Borsatti E, Massarut S, Rossi C, Morassut S, Carbone A. The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. Eur J Nucl Med 1995; 22: 1110-1117.
25. Lee VW, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, Kavanah MT, Ward RJ. A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 1993; 34: 2095-2100.
26. Khalkhali I, Cutrone JA, Mena IG, Diggles LE, Venegas RJ, Vargas HI, Jackson BL, Khalkhali S, Moss RF, Klein SR. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
27. Scopinaro F, Schillaci O, Scarpini M, Mingazzini PL, Di Macio L, Banci M, Danieli R, Zerilli M, Limiti MR, Centi Colella A. Technetium-99m-sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21: 984-987.
28. Burak Z, Argon M, Memis A, Erdem S, Balkan Z, Duman Y, Ustun EE, Erhan Y, Ozkilic H. Evaluation of palpable breast masses with Tc-99m-MIBI: a comparative study with mammography and ultrasonography. Nucl Med Commun 1994; 15: 604-612.
29. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
30. Khalkhali I, Cutrone J, Mena I, Diggles L, Venegas R, Vargas H, Jackson B, Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
31. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994; 21: 432-436.
32. Tiling R, Kress K, Pechmann M, Pfluger T, Kesewitsch P, Tatsch K, Hahn K. Integrated diagnosis of breast turmors: semiquantitative Tc-99m sestamibi imaging versus dynamic MRI. J Nucl Med 1995; 36: 51P.
33. Palmedo H, Schomburg A, Grünwald F, Bender H, Mallmann P, Biersack HJ. Mammoscintigraphy with Tc-99m MIBI: planar and SPECT imaging techniques in patients with suspicious breast nodules. J Nucl Med 1995; 36: 51P-52P.
34. Higley B, Smith FW, Smith T, etal. Technetium-99m-1,2-bis(2-ethoxyethyl)phosphinoethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.
35. Jones S, Hendel RC. Technetiuin-99m tetrofosmin: a new myocardial perfusion agent. J Nucl Med Technol 1993; 21: 191-195.
36. Rambaldi PF, Mansi L, Procaccine E, Di Gregorio F, Del Vecchio E. Breast cancer detection with Tc-99m tetrofosmin. Clin Nucl Med 1995; 20: 703-705.
37. Mansi L, Rambaldi PF, Laprovitera A, Di Gregorio F, Procaccini E. Tc-99m tetrofosmin uptake in breast tumors. J Nucl Med 1995; 36: 83P.
38. Golia R, Miletto P, Spadafora M, De Rimini ML, De Gennaro S, Mazzarella G. Caracciolo F, Mansi L. An improved technique for mammary scintigraphy in patients with breast cancer. J Nucl Biol Med 1994; 38: 236-237.
39. Moretti JL, Caglar M, Duran-Cordobes M, Morere JF. Can nuclear medicine predict response to chemotherapy? Eur J Nucl Med 1995; 22: 97-100.
40. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 1994; 21: 357-362.
41. Ell PJ. Keeping abreast of time. Eur J Nucl Med 1995; 22: 967-969.
42. Piccolo S, Lastoria S, Mainolfi C, Wang H, Muto P, Bazzicalupo L, Salvatore M. Primary breast cancer detection by SMM with Tc-99rn-MDP: comparison with mammographic and histological result in 400 patients. J Nucl Med 1995; 36: 83P.
43. Lastoria S, Piccolo S, Varrella P, Acampa W, Mainolfi C, Vergara E, Wang H, Muto P, Salvatore M. Comparative results of Tc-99m MIBI and Tc-99m MDP scintimammography in patients with breast abnormalities. J Nucl Med 1995; 36: 51P.
44. Ciarmiello A, Del Vecchio S, Potena MI, Mainolfi C, Carriero MV, Tsuruo T, Marone A, Salvatore M. Tc-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma. J Nucl Med 1995; 36: 129P.
45. Maublant JC, Zheng Z, Rapp M, etal. In vitro uptake of Tc-99m teboroxime in carcinoma cell lines and normal cells: comparison with Tc-99m sestamibi and thallium-201. J Nucl Med 1993; 34: 1949-1952.
46. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18) 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
47. Pietrzyk U, Scheidhauer K, Scharl A, Schuster A, Schica H. Presurgical visualisation of primary breast carcinoma with PET emission and transmission imaging. J Nucl Med 1995; 36: 1882-1884.
48. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselmann MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
49. Avril N, Janicke F, Dose J, Bense S, Ziegler S, Zinke M, Laubenbacher C, Romer W, Herz M, Schwaiger M. PET imaging of breast tumors: Münich experience. J Nucl Med 1995; 36: 82P.
50. Avril N, Janicke F, Dose J, Bense S, Ziegler S, Zinke M, Römer W, Weber W, Herz M, Schwaiger M. PET evaluation of axillary lymph node involvement in breast cancer patients. J Nucl Med 1995; 36: 82P.
51. van Eijck CHJ, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J, Jeekel J, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640-643.
52. Taylor JC, Taylor DN, Lowry C, Keeling AA, Bradwell AR, McIntosh A, Rhodes A. Radioimmunoscintigraphy of metastatic breast carcinoma. Eur J Surg Oncol 1992; 18: 57-63.
53. Rijks LJM, de Bruin K, Bakker PJM, Veenhof CHN, Jansenn AGM, van Royen EA. First results with the estrogen receptor radioligand Z-(I-123)MIVE in metastatic breast cancer patients. Eur J Nucl Med 1995; 22: 743.
54. Pace L, D'Aiuto G, Acampora C, Oliviero P, Botti G, Tatangelo F, Cerra M, Salvatore M. Tumour uptake of 57-cobalt-bleomycin in patients with breast cancer. Eur J Cancer 1993; 29A(2): 195-198.
55. Songadele JA, Younes A, Maublant J, etal. Uptake of Tc-99m-tetrofosmin in isolated mitochondria: evidence for an active mechanisms. J Nucl Med 1994; 35: 46P-47P.
56. Ballinger JR, Banneman J, Boxen I, Firby P, Berry BW, Moore MJ, Hartman NG. Accumulation of Tc-99m tetrofosmin in breast tumour cells in vitro: role of multidrug-resistance p-glycoprotein. J Nucl Med 1995; 36: 202P.